PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced new data for its leading candidate, INO-3107, which could transform the treatment of recurrent respiratory papillomatosis (RRP). These findings, shared at the AACR Tumor and Immunology Conference and the International Society of Vaccines Conference, reveal significant potential for reducing surgical interventions in RRP patients.
INO-3107, designed to induce antigen-specific T cell responses against HPV-6 and HPV-11, has shown promising results. In a Phase 1/2 trial, 81% of the 32 participating patients experienced fewer surgeries in the year following treatment compared to the year prior. Notably, 28% of these patients required no further surgical intervention, indicating a complete response.
Dr. Matthew Morrow, INOVIO’s Vice President of Translational Science, highlighted the mechanism of action, stating, “The new immunology data support the proposed mechanism of action of INO-3107 which is to generate an immune response that can seek out and eliminate HPV-6 and HPV-11 infected cells that are the underlying cause of papilloma growth.” He noted the expansion of antigen-specific T cells and their infiltration into airway tissues as key contributors to these positive outcomes.
Dr. Jacqueline Shea, INOVIO’s President and CEO, expressed optimism about the treatment’s impact, saying, “The collective story these data sets provide is compelling. Over 81% of patients who received INO-3107 required fewer surgical procedures compared to baseline, a result that is further supported by the new immunology data demonstrating the ability of INO-3107 to stimulate the immune system and generate antigen-specific T cells that travel to the airways and could eliminate the underlying disease.”
The data also demonstrated that INO-3107 is well tolerated, with the most common treatment-related adverse effects being mild, such as injection site pain and fatigue. These findings support INOVIO’s plan to submit a Biologics License Application under the FDA’s Accelerated Approval Pathway by mid-2025, aiming to make INO-3107 a leading option in managing RRP and improving patients’ quality of life.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.